Divi's Laboratories
DIVISLAB
Divi's Laboratories Market Sentiment
| Timeline | Returns | Volume |
|---|---|---|
| Daily | 6.46% | 11,91,714 |
| Weekly | 6.23% | 20,20,463 |
| Monthly | 5.87% | 78,19,048 |
Divi's Laboratories Performance
| Timeline | Daily | Weekly | Monthly |
|---|---|---|---|
| DIVISLAB | 6.46% | 6.23% | 5.87% |
| Index | - | - | - |
| Peer Avg. | 1.75% | 5.43% | 11.19% |
Divi's Laboratories Fundamentals
| Timeline | PE | PB | EV/EBIDTA | ROE | ROCE | Div. Yield |
|---|---|---|---|---|---|---|
| DIVISLAB | 39.57 | 9.98 | 21.92 | 28.15 | 35.08 | 0.90 |
| Index | 35.44 | 5.98 | 16.81 | 16.99 | 18.41 | 1.19 |
| Peer Avg. | 39.55 | 4.75 | 12.35 | 13.59 | 17.02 | 0.87 |
Divi's Laboratories Key Metrics
| Metrics | Sales Growth | Profit Growth | ROE | ROCE |
|---|---|---|---|---|
| FY '21-22 | 29.59% | 50.02% | 28.15% | 35.08% |
| FY '20-21 | 28.61% | 43.27% | 23.73% | 31.86% |
| FY '19-20 | 8.95% | 2.38% | 19.25% | 25.29% |
Divi's Laboratories Shareholding Pattern
Divi's Laboratories Profit & Loss
| Metrics | Sales | Expenditure | EBITDA | PAT |
|---|---|---|---|---|
| FY '21-22 | 8,919.83 | 5,041.89 | 3,992.91 | 2,954.49 |
| FY '20-21 | 6,884.01 | 4,043.03 | 2,904.03 | 1,969.51 |
| FY '19-20 | 5,352.49 | 3,532.68 | 2,009.56 | 1,374.62 |
Divi's Laboratories Share Price
Divi's Laboratories Limited is an Indian company that manufactures and markets active ingredients (APIs), intermediates and nutrients for export. The company's products include Bupropion HCl, Capecitabine, Carbidopa, Diltiazem HCl, Dextromethorphan Base, Dextromethorphan HBr, Gabapentin, Iopamidol, Iohexol, Irbesartan, Lacosamide, Levetiracetam, Levodopa, Losartan, Nabumetone, Naproxen, Naproxen Sodium, Olmesartan Medoxomil, Pregabalin, Ticagrelor, Triprolidine HCl, Valacyclovir HCl, Valsartan, Venlafaxine HCl and Vigabatrin. In addition to its generic business, the Company supports pharmaceutical companies through custom synthesis businesses in the commercialization of their proprietary products, from gram-scale requirements for clinical trials to launch and late life cycle management. The company's subsidiaries are Divis Laboratories (USA) Inc and Divi's Laboratories Europe AG.